DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tyndale, R. F.
Right arrow Articles by Sellers, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tyndale, R. F.
Right arrow Articles by Sellers, E. M.

Vol. 29, Issue 4, 548-552, April 2001

Variable CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior and Risk

Rachel F. Tyndale and Edward M. Sellers

Centre for Addictions and Mental Health, Toronto, Ontario, Canada (R.F.T., E.M.S.); Departments of Pharmacology, (R.F.T., E.M.S.), Psychiatry, and Medicine (E.M.S.), University of Toronto, Ontario, Canada; and Centre for Research in Women's Health, University of Toronto, Ontario, Canada (R.F.T., E.M.S.)

Nicotine is the psychoactive substance responsible for tobacco dependence; smokers adjust their cigarette consumption to maintain brain nicotine levels. In humans, 70 to 80% of nicotine is metabolized to the inactive metabolite cotinine by the enzyme CYP2A6. CYP2A6 can also activate tobacco smoke procarcinogens [e.g., NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone]. In initial studies we found that there was an under-representation of individuals carrying defective CYP2A6 alleles in a tobacco-dependent population, and that among smokers, those with deficient nicotine metabolism smoked fewer cigarettes. We have since reproduced this data in a prospective smoking study (400 male and female, heavy and light smokers) examining the role of the CYP2A6 genotype on carbon monoxide levels, plasma and urine nicotine and cotinine levels, and cigarette counts. We have also recently identified deletion and duplication variants in the CYP2A6 gene locus and have examined their impact on smoking. These data provide the impetus to examine how inhibition of CYP2A6 activity might be useful in a therapeutic context. Both kinetic and behavioral experiments in human smokers demonstrated that inhibiting CYP2A6 in vivo decreased nicotine metabolism and smoking behavior. This article summarizes the preliminary results from our studies.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Quaak, C. P. van Schayck, A. M. Knaapen, and F. J. van Schooten
Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?
Eur. Respir. J., March 1, 2009; 33(3): 468 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Eval Health ProfHome page
S. L. Ames and C. McBride
Translating Genetics, Cognitive Science, and Other Basic Science Research Findings Into Applications for Prevention
Eval Health Prof, September 1, 2006; 29(3): 277 - 301.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
J. K. Staley, S. Krishnan-Sarin, K. P. Cosgrove, E. Krantzler, E. Frohlich, E. Perry, J. A. Dubin, K. Estok, E. Brenner, R. M. Baldwin, et al.
Human Tobacco Smokers in Early Abstinence Have Higher Levels of beta2* Nicotinic Acetylcholine Receptors than Nonsmokers.
J. Neurosci., August 23, 2006; 26(34): 8707 - 8714.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. Hukkanen, P. Jacob III, and N. L. Benowitz
Metabolism and Disposition Kinetics of Nicotine
Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Spitz, X. Wu, and G. Mills
Integrative Epidemiology: From Risk Assessment to Outcome Prediction
J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M. A. Gyamfi, M. Sakurai, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, et al.
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
Carcinogenesis, December 1, 2004; 25(12): 2451 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. K. Lamba, V. Lamba, K. Yasuda, Y. S. Lin, M. Assem, E. Thompson, S. Strom, and E. Schuetz
Expression of Constitutive Androstane Receptor Splice Variants in Human Tissues and Their Functional Consequences
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 811 - 821.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little
CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review
Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Behav Cogn Neurosci RevHome page
R. A. Bevins and M. I. Palmatier
Extending the Role of Associative Learning Processes in Nicotine Addiction
Behav Cogn Neurosci Rev, September 1, 2004; 3(3): 143 - 158.
[Abstract] [PDF]

Home page
 ChestHome page
V. Batra, A. A. Patkar, W. H. Berrettini, S. P. Weinstein, and F. T. Leone
The Genetic Determinants of Smoking
Chest, May 1, 2003; 123(5): 1730 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. A. Schoedel, E. M. Sellers, R. Palmour, and R. F. Tyndale
Down-Regulation of Hepatic Nicotine Metabolism and a CYP2A6-Like Enzyme in African Green Monkeys after Long-Term Nicotine Administration
Mol. Pharmacol., January 1, 2003; 63(1): 96 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. Ghosheh and E. M. Hawes
Microsomal N-Glucuronidation of Nicotine and Cotinine: Human Hepatic Interindividual, Human Intertissue, and Interspecies Hepatic Variation
Drug Metab. Dispos., December 1, 2002; 30(12): 1478 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Sachse, G. Smith, M. J.V. Wilkie, J. H. Barrett, R. Waxman, F. Sullivan, D. Forman, D. T. Bishop, and C.R. Wolf
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer
Carcinogenesis, November 1, 2002; 23(11): 1839 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Zhang, T. Su, Q.-Y. Zhang, J. Gu, M. Caggana, H. Li, and X. Ding
Genetic Polymorphisms of the Human CYP2A13 Gene: Identification of Single-Nucleotide Polymorphisms and Functional Characterization of an Arg257Cys Variant
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 416 - 423.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.